Loading...

Amy Lin, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address505 Parnassus Avenue
San Francisco CA 94117
Phone415-502-0299
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Oregon Health Sciences UniversityGraduate certificateCurrentBiomedical and Health Informatics
    University of California, San FranciscoFellowship2006Oncology: Genitourinary Medical Oncology
    New York Presbyterian Hospital CornellResidency2002Internal Medicine
    University of Chicago PritzkerM.D.1999School of Medicine
    Harvard UniversityA.B. 1993Biology
    Collapse Awards and Honors
    University of California San Francisco2015Pinnacle "Voice of the Patient" Team Award
    Marin Magazine2015  - 2017[415] Top Doctors
    Cancer and Leukemia Group B (CALGB)2007Young Investigator Award
    American Society of Clinical Oncology2005Young Investigator Award
    American Society of Clinical Oncology2005 Prostate Cancer Symposium Merit Award
    AACR/ASCO2004Clinical Cancer Research Workshop
    University of Chicago1998Calvin Fentress Research Fellowship Award
    Harvard University1992Elizabeth Agassiz Award
    Harvard University1991John Harvard Scholarship for Academic Excellence
    Harvard University1990Harvard College Scholarship

    Collapse Overview 
    Collapse Overview
    Amy M Lin joined the UCSF faculty in 2005 as a genitourinary medical oncologist. From 2005 to 2018, Dr. Lin worked in a multidisciplinary team of medical oncologists, radiation oncologists, and urologic surgical oncologists both at UCSF and the San Francisco Veterans Administration Medical Center providing specialized outpatient patient care to all types of genitourinary malignancies including prostate, kidney, bladder and testicular cancer. In 2018, Dr. Lin joined UCSF’s inpatient hospital-based solid tumor oncology program as a faculty member and chief of clinical operations. She also serves as the Medical Director of Clinical Informatics for Adult Cancer Services at the Helen Diller Comprehensive Cancer Center. Dr. Lin additionally is a core member of UCSF's Cancer Immunotherapy clinical team. She is currently an Associate Professor of Medicine and Urology.

    Dr. Lin’s focus is on improving clinical care workflows to optimize health care delivery. She is interested in how health care technology can enhance certain aspects of patient care and believes that increasing the quality of health care data collection, integration of multi-source patient health care data, and data interoperability are key to these efforts. Dr. Lin has been an active subject matter expert on electronic health record (EHR) clinical workflows within the Cancer Center. She is also a member of the American Society of Clinical Oncology (ASCO) CancerLinQ Research and Publications Committee which is a large scale national effort to collect and analyze real world (non-clinical trial) oncology patient data and outcomes.

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2019 Feb; 17(1):e92-e96. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. PMID: 30327180.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    2. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 06; 23(6):656-e64. Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. PMID: 29487219.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    3. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    4. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 05; 22(5):503-e43. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. PMID: 28314838.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    5. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 04; 35(4):149.e7-149.e13. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. PMID: 28161323.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    6. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. PMID: 27688020.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    7. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. PMID: 25968455.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    8. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. PMID: 25557266.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    9. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. PMID: 25336698.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    10. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 21971890.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    11. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. PMID: 21387258.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    12. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. PMID: 21245693.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    13. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 20884247.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    14. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. PMID: 19147575.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCellsCTClinical Trials
    15. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9. Lin AM, Small EJ. PMID: 18391629.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    16. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91. Lin AM, Small EJ. PMID: 18685361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. PMID: 17645829.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    18. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33. Lin AM, Small EJ. PMID: 17414641.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54. Lin AM, Ryan CJ, Small EJ. PMID: 17161610.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. PMID: 16796694.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    21. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41. Lin AM, Hershberg RM, Small EJ. PMID: 16962496.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    22. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10. Lin AM, Rini BI, Small EJ. PMID: 16643469.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3. Ryan CJ, Lin AM, Small EJ. PMID: 16678059.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans